Expert Interview
A second look at novel therapeutics in development for NMIBC, including; Cretostimogene, TAR-200, TAR-210 Erdafitinib Intravesical Delivery System, and UGN-102
Ticker(s): CGON, JNJ, URGNInstitution: Genesis Healthcare
- Board certified Urologist, Medical Director of Cancer Center, and Primary Investigator of the research division at Institution
- Treats 75 patients with NMIBC per year
- Clinical experience in general urology combined with specialized training in urologic surgical oncology, advanced endoscopic, laparoscopic and robotic surgery
On a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Cretostimogene in NMIBC? TAR-200? TAR-210?
Added By: sara_adminWhat percentage of your patients would be eligible for Cretostimogene, if approved in the future?
What endpoints are you hoping to see in future Phase 3 studies of these candidates?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
